Ortoma AB Class B
SSTO:ORT_B7.15
SEK
-0.04
(-0.56%)
Ortoma AB Class B
STO:ORT_B
(Nasdaq Stockholm)
Recent
price
7.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.- Similar Companies
- Business
- Ortoma AB (publ) is a Sweden-based medical technology company that develops and commercializes artificial intelligence-assisted surgical navigation and preoperative planning systems for orthopedic surgery. The company operates within the healthcare and medical devices sector, providing software and hardware solutions that support orthopedic surgeons across the entire surgical workflow, from diagnostic imaging and preoperative 3D planning to intraoperative computer-assisted navigation and postoperative follow-up for joint replacement and spinal procedures. The company's core offering is centered on the Ortoma Treatment Solution (OTS) platform, which comprises OTS Hip, an AI-driven 3D planning and intraoperative guidance software system designed for total hip arthroplasty; OTS Knee, a digital surgical planning and positioning platform for total and partial knee replacement procedures; OTS Spine, a specialized navigation and planning system tailored for spine surgery and implant placement; Ortoma Plan, an advanced software tool that transforms standard 2D and 3D radiological imaging (such as CT and X-ray data) into detailed anatomical models for customized implant sizing, orientation, and surgical simulation; and Ortoma Guide, a real-time intraoperative optical tracking and navigation system utilizing specialized sensors and surgical instruments to ensure precise implant alignment during operations. Ortoma serves hospitals, orthopedic surgical centers, academic medical institutions, and commercial orthopedic implant manufacturers across Europe, North America, and the Asia-Pacific region. In recent developments, Ortoma has accelerated its global commercialization strategy by entering into strategic distribution and co-marketing agreements with major medical device corporations, including a worldwide partnership with Johnson & Johnson MedTech (DePuy Synthes) for the integration and deployment of its surgical planning and navigation technologies. The company has also expanded its international market access through regulatory clearances, including CE marking under the European Medical Device Regulation (EU MDR) and 510(k) clearances from the U.S. Food and Drug Administration (FDA) for its OTS platform components, alongside commercial entry initiatives in the Japanese market. To support these international commercial activities, ongoing clinical validation studies, and continued software platform development, the company has completed equity financing rounds and capital raises. Founded in 2001, Ortoma AB is headquartered in Gothenburg, Sweden, and its Class B shares are publicly listed on the Nasdaq First North Growth Market.